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Incidence and Mortality in Breast Cancer 
– Are We Doing Better?
Lieveke Ameye, Michel Moreau, Marianne Paesmans
A B S T R A C T
Breast cancer in women is a major health problem: each year, more than 1 million new 
cases are diagnosed worldwide. One in 8 women will be confronted with breast cancer 
during her lifetime. The objective of this review is to present an overview of the epide-
miology of breast cancer i.e. the incidence and mortality rate of breast cancer. In other 
words, how often does breast cancer occur and how often it is lethal? The geographi-
cal variation and the evolution over time are discussed - are we now doing better than 
10 or 20 years ago? Possible ways of preventing breast cancer are also presented.
I N T R O D U C T I O N
Breast cancer in women is a major health problem. Each year, more than 1 million 
new cases are diagnosed worldwide (www.WHO.int). In the United States, the lifetime 
probability of being diagnosed with an invasive breast cancer is 12%; this means that 
1 in 8 women will be confronted with breast cancer during her lifetime (1). The three 
most commonly diagnosed types of cancer in women, in 2008, are breast, lung and 
bronchus, and colorectal cancers accounting for about 50% of estimated cancer cases 
in women. In the United States, among the three, breast cancer is the most frequent 
and accounts for 26% of all new cancer cases among women (1). This review presents 
an overview of the worldwide incidence of breast cancer and of its evolution over time. 
Breast cancer mortality rates are also discussed and possible ways of preventing breast 
cancer are presented.
D E F I N I T I O N S  A N D  D A T A  S O U R C E S
Breast cancer incidence is the number of new breast cancer cases in a specific time 
period per 100 000 subjects, usually expressed as the number of new cases per 100 
000 women in a specific year. Similarly, the breast cancer mortality rate is the rate of 
deaths per 100 000 women in a specific year. Both the incidence and mortality rates 
are standardized, i.e. they are age-adjusted and calculated for a reference population 
in order to improve comparability of incidence and mortality rates between different 
countries.
There are two important epidemiological databases: SEER (Surveillance, Epi-
demiology and End Results, http://seer.cancer.gov ) and CI5 (Cancer Incidence in 
5 continents, http://www-dep.iarc.fr ). The former one presents data for the United 
States while the aim of the latter one is to give an overview worldwide. Both SEER 
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data and CI5 data do not cover the whole population, because 
not all countries participate to the data collection and the 
population in a country is often not completely covered by the 
registration systems. The SEER contains data from 1973-2005, 
while the CI5 contains data from 1960-2002. In contrast to 
CI5, SEER also provides mortality rate estimates.
B R E A S T  C A N C E R  I N C I D E N C E 
W O R D L W I D E  I N  2 0 0 2
A large geographical variation in breast cancer incidence 
was evident in the year 2002 (see Figure 1). The incidence 
rates were high in the more developed areas such as the United 
States, Canada, Australia and in some European countries as 
the United Kingdom and France; all had estimated incidence 
rates of more than 81.7 new cases per 100,000 women. Breast 
cancer incidence was low in Asia and Africa with an incidence 
rate below 42.8 per 100,000 women. Half of the new breast 
cancer cases in 2002 were in industrialized countries—about 
361,000 in Europe (27.3% of cancers in women) and 230,000 
in North America (31.3%) (2). To some extent, the geographi-
cal differences are, undoubtedly, spurious: countries with a 
screening program as the United States, France, the United 
Kingdom have a higher reported incidence rate and countries 
with an incomplete recording have a false lower reported 
breast cancer incidence rate. Genetic background factors as 
the BRCA1 and BRCA2 gene mutation may account for up 
to 10% of breast cancer cases in developed countries (3), but 
their prevalence in the population is too low to explain much 
of the international variation. The international variation is 
mainly due to the exposure to known or suspected risk fac-
tors related to lifestyle or environment (2;4;5). This is evident 
from migrants studies, which show quite clearly that incidence 
rises after migration from low to high incidence countries, 
particularly if the move takes place at young ages (6;7). For 
example, the incidence rates for Japanese women living in San 
Francisco or Los Angeles are twice those of Japanese women 
in Japan. Apparently, breast cancer risk among migrants ap-
proaches the risk among native populations and it is affected 
by the time since migration: recent Asian migrants have a 
lower risk than migrants who have lived in the Unites States 
for more than 20 years.
E V O L U T I O N  O F  B R E A S T  C A N C E R 
I N C I D E N C E  O V E R  T I M E
Table 1 presents the evolution of breast cancer incidence 
over time for selected countries.
Until the year 2002, incidence rates of breast cancer were 
increasing in most countries, and the largest changes were 
usually seen in countries with a previously low incidence 
rate (8). Between 1990 and 2002, there has been an overall 
increase in incidence rates of about 0.5% annually. However, 
cancer registries in China were recording annual increases in 
incidence of 3% to 4%, and increases were not much lower in 
those elsewhere in eastern Asia, (9-11).
Main risk factors for breast cancer are related to the 
female hormones estrogen and progesterone produced in 
the body or given as hormone replacement therapy. Changes 
in reproductive factors (age at menarche, age at menopause, 
number of children), use of postmenopausal hormone replace-
ment therapy, and lifestyle factors (body size/obesity, alcohol 
consumption, physical activity) have contributed to the breast 
cancer increase over the last 20 years in developed countries 
(12-14). Such changes to the environment or society influence 
a specific generation or birth cohort and are therefore called 
cohort effects. Each successive generation (or birth cohort) 
is influenced by intervening changes in environment and so-
ciety and the incidence increases when the oldest generation 
is replaced by the most recent one who was more exposed to 
these risk factors. Cohort effects result in a slow increase of 
the incidence. Period effects on the other hand are responsible 
for sudden increases/decreases in breast cancer incidence. For 
example, the introduction of a screening program in a country 
results in an increase of the reported incidence due to the fact 
that breast cancer tumours are detected earlier than before. 
Other examples of period effects are new diagnostic techniques, 
a carcinogen that acts in the late stage of tumorigenesis, or an 
improvement in the completeness of data registration (15). A 
period effect influences all generations in the same way.
Figure 2 shows the breast cancer incidence rate by age group. 
In the less developed countries with a low incidence of breast 
cancer, the incidence rate is stable or even slightly decreas-
ing after menopause. This is in contrast to more developed 
countries with a high incidence of breast cancer, where the 
incidence rate still increases even after the menopause. The 
increase is slower than before the menopause, which can be 
explained by the decreasing oestrogen level in postmenopausal 
patients. The difference in the two age-specific patterns, be-
tween high and low incidence countries, has been attributed 
to increasing incidence among young birth cohorts in low-risk 
countries due to environmental and lifestyle changes in these 
countries, but it could also indicate that oestrogen receptor 
positive tumours are more prevalent in the high incidence 
countries, e.g. the United States (16).
B R E A S T  C A N C E R  I N C I D E N C E 
D E C R E A S I N G  S I N C E  2 0 0 3 ?
In 2002, a report of the randomized trial of the Women’s 
Health Initiative was published, reporting a significant increase 
in breast cancer associated with the use of estrogen-progestin 
combination therapy (17). The year after, in 2003, breast cancer 
incidence decreased in the United Stated by 6.7% compared to 
the rate in 2002 (18). In 2004, the incidence rate stabilized at 
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TABLE 1. Age-standardized (world population) breast cancer incidence rate per 100,000 women (International Agency 
for Reseach on Cancer (IARC))
1973-1977 1978-1982 1983-1987 1988-1992 1993-1997 1998-2002
North Amercia, SEER, white 74.96 73.40 85.92 91.09 92.55 97.1
China, Hong Kong 29.69 28.41 32.35 34.05 36.41 41.3
Japan, Nagasaki City 18.76 22.82 27.80 32.83 36.95 38.1
Denmark 61.00 64.19 68.83 75.87 80.02 83.7
Norway 49.03 50.88 54.13 55.80 67.07 71.0
Italy, Parma Province 60.30 64.50 74.98 84.08 96.3
Australia, New South Wales 53.25 53.11 57.75 67.24 80.73 83.1
New Zealand 64.47 75.37 75.77 86.5
FIGURE 1. Age-standardized (world population) breast cancer incidence rate per 100,000 women (International Agency for Re-
seach on Cancer (IARC), estimates for the year 2002).
the level of 2003. Changes in reproductive factors, in the use 
of hormone replacement therapy (HRT) during menopause, 
in mammographic screening, in environmental exposures, 
and in diet could have been an explanation for the sudden 
decrease. Although screening mammography decreased by 
3.2% between 2000 and 2003 (18), the decrease was probably 
too small to explain the change in the breast cancer incidence 
rate. The most likely explanation is the substantial change in 
the use of HRT between 2002 and 2003. By the end of 2002, 
the use of HRT was decreased in the United States by 38%, 
approximately 20 million prescriptions less in 2003 compared 
to 2002 (19;20). The decrease of HRT as the main reason for 
the sudden decrease in breast cancer incidence was confirmed 
by the observation of a larger decrease in estrogen receptor 
positive tumours compared to estrogen receptor negative tu-
mours: the incidence rate in women aged 50 to 69 decreased 
between the year 2001 and 2004 by 14.7% in estrogen receptor 
positive tumours, while only a decline of 1.7% was observed in 
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estrogen receptor negative tumours (18). A similar decreasing 
trend in breast cancer incidence after a decrease in the HRT 
has been observed in Australia (21), Canada (22), Germany 
(23) and France (24). A small impact of the decrease in the use 
of HRT on breast cancer incidence is expected in countries 
with a low HRT use such as Spain, the Netherlands or Italy 
(5% to 8%), in contrast to countries with a high HRT use such 
as Belgium or France (32% to 38%) (25;26).
B R E A S T  C A N C E R  M O R T A L I T Y 
W O R L D W I D E  I N  2 0 0 2
Breast cancer is still the leading cause of cancer mortality 
in women: 1 in 7 female cancer deaths is due to breast cancer 
(2). Figure 3 shows the geographical variation in breast cancer 
mortality. Overall, the differences are less pronounced than 
those of incidence. Countries with high incidence of breast 
cancer like Canada and the United Kingdom is logical to fig-
ure with high breast cancer mortality rates: age-standardized 
mortality rate above 29.6 per 100,000 women. Unfortunately, 
some countries in Africa with low incidence rates have also a 
high breast cancer mortality. More than 55% of breast-can-
cer–related deaths, occur in low- and middle-income countries 
(www.iarc.fr). Little attention is currently paid to breast care 
in these less developed countries due to other health priorities. 
Asian countries have the lowest breast cancer mortality rates: 
less than 10.5 per 100,000 women.
B R E A S T  C A N C E R  M O R T A L I T Y  
B Y  R A C E  A N D  E T H N I C I T Y
Mortality rates differ by race and ethnicity. Although 
breast cancer mortality decreases overall in the United States 
since 1990, this is particularly true in white women. African-
American women are more likely to be diagnosed with poor 
prognosis breast cancers (late stage, large size, lymph node 
positive, estrogen receptor negative) compared to white Ameri-
can women; Asian/Pacific Island women tend to have breast 
cancers of better prognosis (early stage, small size, lymph 
node negative, estrogen receptor positive) (27-30). A possible 
explanation might be a difference in attending screening mam-
mography resulting in differences in tumor stage and size at 
diagnosis (31;32). Socioeconomic factors and consequently 
inadequate access to appropriate treatment might also play 
an important role (30;33;34).
B R E A S T  C A N C E R  M O R T A L I T Y 
D E C R E A S E  I N  T H E  L A S T  2 0  Y E A R S  
D U E  T O  M A M M O G R A P H Y  S C R E E N I N G 
A N D  A D J U V A N T  T H E R A P Y
In the United States, breast cancer mortality rate was 49.7 
per 100,000, but dropped to 38.0 by the year 2000: a decrease 
of 24% (35). Similar decreases were observed in other countries 
FIGURE 2. Breast cancer incidence rate per 100,000 women by age group (0-14, 15-44, 45-54, 55-64, 65+) (International Agency for 
Reseach on Cancer (IARC), estimates for the year 2002).
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(8). A plausible explanation for these decreases is the early 
detection of breast cancer tumours by mammography screen-
ing. This has been investigated in randomized controlled trials 
with two arms: an intervention group undergoing annual mam-
mography screening and a control group receiving the usual 
medical care. In women aged 50 or older it has been shown that 
screening reduces breast cancer mortality by approximately 
25% (36) but there is less evidence that screening is efficient 
for women younger than 50 years: a small, but statistically non 
significant reduction in breast cancer mortality at 10-year fol-
low-up due to mammography screening was shown (37).
Between 1985 and 2000, the use of mammography screening 
increased highly. While 75% of the women did not undergo 
screening in the year 1985, this figure decreased to less than 
20% in the year 2000 (38). Not only the use of mammography 
screening has changed over time, but adjuvant treatments have 
also improved. Nowadays, the combination of chemotherapy 
and endocrine therapy is much more frequently applied than 
20 years ago (39). Berry et al. (40) used modeling techniques 
to assess the contributions of screening mammography and 
adjuvant therapy to the reduction in breast cancer mortality, 
in the United States, from 1975 till 2000. Seven groups of 
investigators developed, independently of each other, a model 
of breast cancer incidence and mortality. In the seven models, 
the proportion of the total reduction in breast cancer mortality 
rate from 1975 to 2000 attributed to screening varied from 28% 
to 65% (median 46%); the proportion attributed to adjuvant 
therapy varied from 35% to 72% (median 54%).
B R E A S T  C A N C E R  P R E V E N T I O N ?
Most of the known breast cancer risk factors are not pre-
ventable since they are related to the reproductive cycle and 
inheritance (BRCA1 and BRCA2 gene mutation) (2;4;5;41). 
Unfortunately, only half of the breast cancer cases can be 
explained by the currently identifiable risk factors (6). It is 
hypothesized that non-estrogenic environmental carcinogens 
(e.g., excess ionizing radiation, human-made chemicals, or 
biological agents such as viruses), which may cause genetic 
alterations, may also play an important role in the develop-
ment of breast cancer. But it is difficult to provide the evi-
dence because the majority of environmental exposure has 
mainly effects on the development of breast cancer through 
interactions (environment-environment, environment-genetic 
predisposition and environment-time of exposure): there is a 
greater vulnerability during in utero period, early woman’s 
life, or during early breasts development (41;42). Moreover, 
potential environmental carcinogens are widely prevalent with 
the result that it is difficult to find non-exposed women. And 
finally, breast cancer is not one entity but at least two (pre and 
post- menopausal) or according to ER/PR receptors status 
FIGURE 3. Age-standardized (world population) breast cancer mortality rate per 100,000 women (International Agency for Re-
search on Cancer (IARC), estimates for the year 2002).
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up to six subgroups with different etiologic factors causally 
related to the disease (4).
Until recently, there was no way to prevent breast cancer. 
The primary message of health care awareness programs was 
that early detection offered the best protection against breast 
cancer, so-called secondary prevention (43). Nowadays, also 
primary prevention is investigated. In women with a high risk 
of developing breast cancer, chemoprevention could be consid-
ered. Large trials have shown that selective estrogen receptor 
modulators (SERMs) reduce the risk of invasive breast cancer 
by about 50% (44). These SERMs reduce the risk of estrogen 
receptor positive cancers, but not of estrogen receptor nega-
tive cancers (45-47). Reported adverse events of SERMs are 
an increase in thromboembolic disease and the development 
of endometrial cancer. Data on the efficacy of aromatase in-
hibitors for adjuvant therapy in breast cancer have shown that 
these agents possess significant chemopreventive effectiveness 
(48;49). Their value in chemoprevention is limited by potential 
adverse effects such as bone mineral loss with an increased 
risk of fractures (50). In selected very high risk patients i.e. 
those with BRCA1 and BRCA2 gene mutation, prophylactic 
bilateral mastectomy or prophylactic bilateral oophorectomy 
might be reasonably considered (43).
Use of shorter duration HRT or better targeted might 
also prevent development of some estrogen positive breast 
cancers (18).
C O N C L U D I N G  D I S C U S S I O N
A large geographical variation in breast cancer incidence 
is present. The environment has undoubtly a major impact on 
the risk of developing breast cancer. This means that where 
you are living really matters. But within a specific country, the 
incidence rate varies with race and ethnicity: breast cancer is 
more common in African American women than it is among 
Asian Americans. Breast cancer incidence was increasing year 
by year for a long period of time. But in 2003, a sudden drop in 
the incidence was noticed in the United States and shortly after, 
similar results were reported in Australia, Canada, Germany 
and France. The most plausible explanation for this drop is the 
decline in the use of HRT in the preceeding years as the drop 
is only seen in estrogen receptor positive tumours.
Future will reveal if the incidence rates will decrease further, 
become stable or increase again; in the latter case, this would 
mean that HRT has only accelerated the induction of breast 
cancer but these cases would be unavoidable. In countries 
with a low use of HRT, no decrease in the incidence rates has 
been reported so far. In some European countries as Spain 
and Italy, HRT is less frequently used and its use is of shorter 
duration compared with the United States.
Breast cancer mortality rates are declining in the last 20 
years thanks to mammography screening and adjuvant therapy. 
Further improvements are expected due to the application of 
neoadjuvant therapy and the use of Trastuzumab in case of 
Her2 positive tumours, …
Are we doing better? The answer is yes!
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